Drugs / VXA-CoV2-3.3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06672055 | Oct 2024 → May 2027 expected | COVID-19 | Vaxart | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXA-CoV2-3.3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06672055 ↗ |
| Modality | Vaccine | “VXA-CoV2-3.3 (KP.2 vaccine)” NCT06672055 ↗ |
| Route | Oral | “Tablets for oral use.” NCT06672055 ↗ |